Drug intelligence / Profile preview

TPX-107

Development stage
Unknown
Lead developer
Tego Science
Modality
Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Ophthalmic
01

Overview

TPX-107 is an autologous cell therapy composed of cultured corneal cells, developed by Tego Science for the treatment of corneal defects. The therapy involves the ex vivo expansion of a patient's own corneal cells, which are then transplanted to the site of the defect to promote regeneration of the corneal epithelium and restore ocular surface integrity. This approach is typically utilized for patients with severe corneal surface injuries or limbal stem cell deficiency where the eye's natural regenerative capacity is compromised. As an autologous treatment, it minimizes the risk of immune rejection by using the patient's own biological material.

Beyond the preview

Go deeper on TPX-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPX-107.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call